Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RVMD Revolution Medicines, Inc.

盘前交易 08-16 08:47:43 EDT

43.52

+0.94

+2.21%

最高44.20	最低42.62	成交量111.44万
今开43.58	昨收42.58	日振幅3.71%
总市值72.70亿	流通市值70.98亿	总股本1.67亿
成交额4,851万	换手率0.68%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"RVMD","market":"US","secType":"STK","nameCN":"Revolution Medicines, Inc.","latestPrice":43.52,"timestamp":1723752000000,"preClose":42.58,"halted":0,"volume":1114449,"delay":0,"floatShares":163086367,"shares":167038943,"eps":-3.579193,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.94,"latestTime":"08-16 08:47:43 EDT","open":43.58,"high":44.2,"low":42.62,"amount":48514625.159763,"amplitude":0.037107,"askPrice":48.3,"askSize":100,"bidPrice":35,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-3.579193,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1723815000000},"adr":0,"listingDate":1581570000000,"adjPreClose":43.52,"postHourTrading":{"tag":"盘后","latestPrice":43.52,"preClose":43.52,"latestTime":"18:23 EDT","volume":253697,"amount":11040892.88,"timestamp":1723760609038},"volumeRatio":1.1058976510500746,"impliedVol":0.3729,"impliedVolPercentile":0.004},"requestUrl":"/m/hq/s/RVMD","defaultTab":"news","newsList":[{"id":"2457058818","title":"Revolution Medicines Inc    预计每股亏损 77 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457058818","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457058818?lang=zh_cn&edition=full","pubTime":"2024-08-06 10:03","pubTimestamp":1722909825,"startTime":"0","endTime":"0","summary":"   * Revolution Medicines Inc    将于8月7日公布截至2024年6月30日的财报，预计该公司的季度收入将出现下降。* 根据LSEG的数据，14位分析师的平均预期显示，这家总部位于加利福尼亚州红木城的公司的营收将从去年同期的382万美元下降80.4%，至75万美元。* LSEG 分析师对 Revolution Medicines Inc 的平均预期是每股亏损 77 美分。* 华尔街对Revolution Medicines Inc的12个月目标价中位数为57.00美元，高于其最新收盘价42.48美元。8月6日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Revolution Medicines Inc    预计每股亏损 77 美分 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD"],"gpt_icon":0},{"id":"2457877308","title":"Revolution Medicines, Inc.盘中异动 早盘股价大跌6.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2457877308","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457877308?lang=zh_cn&edition=full","pubTime":"2024-08-05 21:41","pubTimestamp":1722865317,"startTime":"0","endTime":"0","summary":"北京时间2024年08月05日21时41分，Revolution Medicines, Inc.股票出现异动，股价快速下跌6.18%。Revolution Medicines, Inc.股票所在的生物技术行业中，整体跌幅为2.33%。Revolution Medicines, Inc.公司简介：Revolution Medicines Inc是一家临床阶段的精密肿瘤学公司，致力于开发新颖的靶向疗法，以抑制臭名昭著的生长和生存途径内的难以捉摸的前沿靶标，尤其侧重于RAS和mTOR信号通路。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408052141579f10759b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408052141579f10759b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2452534436","title":"巴克莱：维持Revolution Medicines(RVMD.US)评级，由增持调整至增持评级, 目标价由52.00美元调整至54.","url":"https://stock-news.laohu8.com/highlight/detail?id=2452534436","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452534436?lang=zh_cn&edition=full","pubTime":"2024-07-18 23:38","pubTimestamp":1721317111,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2451930059","title":"HC Wainwright &amp; Co.：维持Revolution Medicines(RVMD.US)评级，由买入调整至买入评级, 目标价由44.","url":"https://stock-news.laohu8.com/highlight/detail?id=2451930059","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451930059?lang=zh_cn&edition=full","pubTime":"2024-07-16 19:49","pubTimestamp":1721130564,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2451614709","title":"Revolution Medicines Inc: BofA全球研究将价格目标从48美元提高到55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451614709","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451614709?lang=zh_cn&edition=full","pubTime":"2024-07-16 18:12","pubTimestamp":1721124753,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2451961524","title":"Revolution Medicines股票：H.c. Wainwright将目标价从44美元提高至56美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2451961524","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451961524?lang=zh_cn&edition=full","pubTime":"2024-07-16 18:05","pubTimestamp":1721124346,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2451966289","title":"Revolution Medicines Inc：摩根大通将目标价从42美元上调至55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451966289","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451966289?lang=zh_cn&edition=full","pubTime":"2024-07-16 17:43","pubTimestamp":1721123007,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2451966298","title":"Revolution Medicines(RVMD)盘前涨超3% 旗下抑制剂RMC-6236于1b期临床试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2451966298","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451966298?lang=zh_cn&edition=full","pubTime":"2024-07-16 17:41","pubTimestamp":1721122873,"startTime":"0","endTime":"0","summary":"金吾财讯 | Revolution Medicines(RVMD)盘前涨超3%，截至发稿，报47.47美元。消息面上，公布其在研泛RAS抑制剂RMC-6236于1b期临床试验的积极结果。分析显示，RMC-6236单药作为二线疗法可延长带有KRAS G12X突变患者的中位无进展生存期(PFS)达8.1个月，并使此类患者群体的疾病控制率(DCR)达近90%。据悉，根据Revolution Medicines，RMC-6236是针对所有主要RAS突变型的首个靶向在研疗法。RAS突变是驱动PDAC疾病进展的主要因素。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/MGY3NWNiZjgxNDI5NTMwNTcxNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGY3NWNiZjgxNDI5NTMwNTcxNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"277815","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVMD","BK4139","BK1583","BK1141","03347","BK1576"],"gpt_icon":0},{"id":"2451896514","title":"Revolution Medicines(RVMD.US)盘前涨3.2%报47.47美元。消息上公司公布其在研泛RAS抑制剂RMC-6236于1b期临床试验的积极结果。","url":"https://stock-news.laohu8.com/highlight/detail?id=2451896514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451896514?lang=zh_cn&edition=full","pubTime":"2024-07-16 17:23","pubTimestamp":1721121814,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4211","RVMD","BK1141","BK4195","03347","BK1583","BK1576","BK4139","PFS"],"gpt_icon":0},{"id":"2451516965","title":"美股异动丨Revolution Medicines盘前涨3.2% 在研新药临床试验积极Revolution Medicines(RVMD.","url":"https://stock-news.laohu8.com/highlight/detail?id=2451516965","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451516965?lang=zh_cn&edition=full","pubTime":"2024-07-16 17:21","pubTimestamp":1721121676,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","BK1576","BK1583","RVMD","03347","BK1141"],"gpt_icon":0},{"id":"2451959215","title":"美国研究综述-贝莱德、高盛、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2451959215","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451959215?lang=zh_cn&edition=full","pubTime":"2024-07-16 15:29","pubTimestamp":1721114999,"startTime":"0","endTime":"0","summary":"    路透7月16日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括贝莱德、高盛和 Netflix。股票条目按字母顺序排列。Group Co   ：Roth MKM将目标价从4美元下调至3.5美元             * 沃特斯公司  ：TD Cowen将目标价从358美元下调至325美元","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLDB","LU0731783394.SGD","QTRX","MYGN","PPG","INCY","LU0170899867.USD","LU0096364046.USD","SG9999014914.USD","JJSF","NFLX","IE00BFXG1179.USD","GS","BK4212","LU1267930730.SGD","SG9999003800.SGD","GH","LU0511384066.AUD","AMP","LU0476273544.USD","SPGI","AVGO","BK4585","COO","PET","PGR","PK","GLPI","IE00B19Z8W00.USD","BK4566","MCO","WGS","LXEO","RVMD","LU0426412945.USD","SFBS","LU0198837287.USD","MSCI","SG9999017495.SGD","IE00BKVL7J92.USD","BRKR","LU0289961442.SGD","BK4588","GNRC","BK4587","SEM","LU1074936037.SGD","TXG","BLK","WAT"],"gpt_icon":0},{"id":"2451938428","title":"Revolution Medicines(RVMD.US)公布在研泛RAS抑制剂RMC-6236于1b期临床试验积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2451938428","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451938428?lang=zh_cn&edition=full","pubTime":"2024-07-16 10:58","pubTimestamp":1721098728,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月16日，Revolution Medicines公布其在研泛RAS抑制剂RMC-6236于1b期临床试验的积极结果。该公司已着手准备该药物作为PDAC患者二线疗法的全球性随机临床3期试验。根据Revolution Medicines，RMC-6236是针对所有主要RAS突变型的首个靶向在研疗法。致癌RAS蛋白驱动高达30%的所有人类癌症，尤其是在PDAC、非小细胞肺癌和结直肠癌中最为显著。RMC-6236是一款口服、可靶向突变和野生型RAS在GTP结合状态下的选择性抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","03347","BK1583","BK4139","RVMD","BK1576"],"gpt_icon":0},{"id":"2451093844","title":"【Revolution Medicines(RVMD.US)公布在研泛RAS抑制剂RMC-6236于1b期临床试验积极结果】智通财经APP获悉，7月16日，Revolution Medicines(RVMD.","url":"https://stock-news.laohu8.com/highlight/detail?id=2451093844","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451093844?lang=zh_cn&edition=full","pubTime":"2024-07-16 10:58","pubTimestamp":1721098728,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","BK1576","PFS","BK1583","RVMD","BK4195","BK4211","03347","BK1141"],"gpt_icon":0},{"id":"2451870109","title":"Revolution Medicines Inc : Oppenheimer将目标价从45美元升至55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451870109","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451870109?lang=zh_cn&edition=full","pubTime":"2024-07-16 10:39","pubTimestamp":1721097550,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2451496246","title":"Revolution Medicines Inc：预计截至2024年12月31日的净亏损将在5.6亿美元至6亿美元之间。","url":"https://stock-news.laohu8.com/highlight/detail?id=2451496246","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451496246?lang=zh_cn&edition=full","pubTime":"2024-07-15 20:04","pubTimestamp":1721045091,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","RVMD"],"gpt_icon":0},{"id":"2450587829","title":"Revolution Medicines(RVMD.US)获巴克莱首次覆盖，给予增持评级, 目标价52.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2450587829","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450587829?lang=zh_cn&edition=full","pubTime":"2024-07-12 20:32","pubTimestamp":1720787569,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2450302121","title":"Revolution Medicines Inc.: 巴克莱银行开始覆盖并给予超重评级和52美元的目标价。","url":"https://stock-news.laohu8.com/highlight/detail?id=2450302121","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450302121?lang=zh_cn&edition=full","pubTime":"2024-07-12 18:07","pubTimestamp":1720778833,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0345777147.USD","LU0345777659.USD","LU0047473722.EUR","LU1791807156.HKD","LU0550127509.SGD","BK4207","LU0047473722.SGD","BK4139","BCS","LU0106831901.USD","BK4521","BK5152","LU0964806797.USD","LU1078025761.USD","LU0161305163.EUR","RVMD","LU1668664300.SGD","BARC.UK"],"gpt_icon":0},{"id":"2449770395","title":"Revolution Medicines, Inc.盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449770395","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449770395?lang=zh_cn&edition=full","pubTime":"2024-07-08 21:31","pubTimestamp":1720445481,"startTime":"0","endTime":"0","summary":"北京时间2024年07月08日21时31分，Revolution Medicines, Inc.股票出现异动，股价急速上涨5.01%。Revolution Medicines, Inc.股票所在的生物技术行业中，整体涨幅为0.16%。Revolution Medicines, Inc.公司简介：Revolution Medicines Inc是一家临床阶段的精密肿瘤学公司，致力于开发新颖的靶向疗法，以抑制臭名昭著的生长和生存途径内的难以捉摸的前沿靶标，尤其侧重于RAS和mTOR信号通路。消息层面，截至21时31分，《富瑞集团首予Revolution Medicines买入评级，目标价63美元》资讯为影响Revolution Medicines, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407082131229f1ee74d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407082131229f1ee74d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2449706437","title":"Revolution Medicines(RVMD.US)获杰富瑞投资银行首次覆盖，给予买入评级, 目标价63.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2449706437","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449706437?lang=zh_cn&edition=full","pubTime":"2024-07-08 20:59","pubTimestamp":1720443568,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["RVMD","BK4139"],"gpt_icon":0},{"id":"2444711315","title":"Revolution Medicines, Inc.盘中异动 大幅下跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2444711315","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2444711315?lang=zh_cn&edition=full","pubTime":"2024-06-18 02:25","pubTimestamp":1718648709,"startTime":"0","endTime":"0","summary":"北京时间2024年06月18日02时25分，Revolution Medicines, Inc.股票出现异动，股价大幅下挫5.08%。Revolution Medicines, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。Revolution Medicines, Inc.公司简介：Revolution Medicines Inc是一家临床阶段的精密肿瘤学公司，致力于开发新颖的靶向疗法，以抑制臭名昭著的生长和生存途径内的难以捉摸的前沿靶标，尤其侧重于RAS和mTOR信号通路。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240618022510aef54ccd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240618022510aef54ccd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RVMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revmed.com","stockEarnings":[{"period":"1week","weight":0.0367},{"period":"1month","weight":-0.0695},{"period":"3month","weight":0.1043},{"period":"6month","weight":0.4748},{"period":"1year","weight":0.4555},{"period":"ytd","weight":0.5174}],"compareEarnings":[{"period":"1week","weight":0.0423},{"period":"1month","weight":-0.0209},{"period":"3month","weight":0.0446},{"period":"6month","weight":0.1072},{"period":"1year","weight":0.258},{"period":"ytd","weight":0.1636}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revolution Medicines, Inc.成立于2014年10月，是特拉华州的一家公司。该公司是一家临床阶段的精准肿瘤学公司，专注于开发靶向疗法，以抑制RAS成瘾癌症的前沿靶点。该公司拥有先进的基于结构的药物发现能力，其基础是深厚的化学生物学和癌症药理学知识以及创新的专有技术，能够创造适合非常规结合位点的小分子。该公司对癌症的遗传驱动因素和适应性耐药机制的了解，加上强大的药物发现和药物化学能力，指导建立了一个针对RAS通路和相关通路中的关键信号节点的深层管道。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.002389},{"month":2,"riseRate":0.75,"avgChangeRate":0.00657},{"month":3,"riseRate":0.6,"avgChangeRate":-0.008788},{"month":4,"riseRate":0.6,"avgChangeRate":0.034923},{"month":5,"riseRate":0.4,"avgChangeRate":-0.035334},{"month":6,"riseRate":1,"avgChangeRate":0.06444},{"month":7,"riseRate":0.4,"avgChangeRate":-0.00346},{"month":8,"riseRate":0.6,"avgChangeRate":0.072081},{"month":9,"riseRate":0.25,"avgChangeRate":-0.016205},{"month":10,"riseRate":0.5,"avgChangeRate":-0.079994},{"month":11,"riseRate":0.75,"avgChangeRate":0.181921},{"month":12,"riseRate":0.5,"avgChangeRate":0.014112}],"exchange":"NASDAQ","name":"Revolution Medicines, Inc.","nameEN":"Revolution Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Revolution Medicines, Inc.,RVMD,Revolution Medicines, Inc.股票,Revolution Medicines, Inc.股票老虎,Revolution Medicines, Inc.股票老虎国际,Revolution Medicines, Inc.行情,Revolution Medicines, Inc.股票行情,Revolution Medicines, Inc.股价,Revolution Medicines, Inc.股市,Revolution Medicines, Inc.股票价格,Revolution Medicines, Inc.股票交易,Revolution Medicines, Inc.股票购买,Revolution Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Revolution Medicines, Inc.(RVMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Revolution Medicines, Inc.(RVMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}